|
π¦
|
MYD88 L265P somatic mutation in WaldenstrΓΆm's macroglobulinemia.
19 auth.
S. Treon,
Lian Xu,
Guang Yang,
Yangsheng Zhou,
Xia Liu,
Yanglin Cao,
P. Sheehy,
R. Manning,
C. Patterson,
C. Tripsas,
...
L. Arcaini,
G. Pinkus,
S. Rodig,
A. Sohani,
N. Harris,
J. Laramie,
D. Skifter,
S. Lincoln,
Z. Hunter
|
10 |
2012 |
10
π¦
|
|
π
|
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
17 auth.
F. Davies,
N. Raje,
T. Hideshima,
S. Lentzsch,
G. Young,
Y. Tai,
B. Lin,
K. Podar,
Deepak K. Gupta,
D. Chauhan,
...
S. Treon,
P. Richardson,
R. Schlossman,
G. Morgan,
G. Muller,
D. Stirling,
K. Anderson
|
9 |
2001 |
9
π
|
|
π
|
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
13 auth.
T. Hideshima,
D. Chauhan,
Y. Shima,
N. Raje,
F. Davies,
Y. Tai,
S. Treon,
B. Lin,
R. Schlossman,
P. Richardson,
...
G. Muller,
D. Stirling,
K. Anderson
|
9 |
2000 |
9
π
|
|
π
|
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
11 auth.
R. Owen,
S. Treon,
A. Al-Katib,
R. Fonseca,
P. Greipp,
M. McMaster,
...
E. Morra,
G. Pangalis,
J. S. San Miguel,
A. Branagan,
M. Dimopoulos
|
9 |
2003 |
9
π
|
|
π
|
The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.
72 auth.
E. Campo,
E. Jaffe,
J. Cook,
L. QuintanillaβMartinez,
S. Swerdlow,
K. Anderson,
P. Brousset,
L. Cerroni,
L. de Leval,
S. Dirnhofer,
A. Dogan,
A. Feldman,
F. Fend,
J. Friedberg,
P. Gaulard,
...
P. Ghia,
S. Horwitz,
R. King,
G. Salles,
J. San-Miguel,
J. Seymour,
S. Treon,
J. Vose,
E. Zucca,
R. Advani,
S. Ansell,
W. Au,
C. Barrionuevo,
P. Bergsagel,
W. Chan,
J. Cohen,
A. Davies,
B. Falini,
I. Ghobrial,
J. Goodlad,
J. Gribben,
E. Hsi,
B. Kahl,
W. Kim,
Shaji K. Kumar,
A. LaCasce,
C. Laurent,
G. Lenz,
J. Leonard,
M. Link,
A. LΓ³pez-Guillermo,
M. Mateos,
E. Macintyre,
A. Melnick,
F. Morschhauser,
S. Nakamura,
M. Narbaitz,
A. Pavlovsky,
S. Pileri,
M. Piris,
B. Pro,
S. Rajkumar,
S. Rosen,
B. Sander,
L. Sehn,
M. Shipp,
Sonali M. Smith,
L. Staudt,
C. Thieblemont,
T. Tousseyn,
W. Wilson,
T. Yoshino,
P. Zinzani,
M. Dreyling,
D. Scott,
J. Winter,
A. Zelenetz
|
9 |
2022 |
9
π
|
|
π¦
|
Ibrutinib in previously treated WaldenstrΓΆm's macroglobulinemia.
27 auth.
S. Treon,
C. Tripsas,
K. Meid,
D. Warren,
Gaurav Varma,
R. Green,
K. Argyropoulos,
Guang Yang,
Yanglin Cao,
Lian Xu,
C. Patterson,
S. Rodig,
J. Zehnder,
J. Aster,
N. Harris,
...
Sandra Kanan,
I. Ghobrial,
J. Castillo,
J. Laubach,
Z. Hunter,
Z. Salman,
Jianling Li,
M. Cheng,
F. Clow,
T. Graef,
M. Palomba,
R. Advani
|
9 |
2015 |
9
π¦
|
|
π
|
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
14 auth.
N. Mitsiades,
C. Mitsiades,
V. Poulaki,
D. Chauhan,
G. Fanourakis,
Xuesong Gu,
Charles Bailey,
Marie G. Joseph,
T. Libermann,
S. Treon,
...
N. Munshi,
P. Richardson,
T. Hideshima,
K. Anderson
|
9 |
2002 |
9
π
|
|
π
|
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
9 auth.
N. Mitsiades,
C. Mitsiades,
V. Poulaki,
D. Chauhan,
P. Richardson,
T. Hideshima,
...
N. Munshi,
S. Treon,
K. Anderson
|
9 |
2002 |
9
π
|
|
π
|
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
18 auth.
Deepak K. Gupta,
S. Treon,
Y. Shima,
T. Hideshima,
K. Podar,
Y. Tai,
B. Lin,
S. Lentzsch,
F. Davies,
D. Chauhan,
...
R. Schlossman,
P. Richardson,
P. Ralph,
Lei Wu,
F. Payvandi,
G. Muller,
D. Stirling,
K. Anderson
|
9 |
2001 |
9
π
|
|
π
|
Activation of NF-ΞΊB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
11 auth.
C. Mitsiades,
N. Mitsiades,
V. Poulaki,
R. Schlossman,
M. Akiyama,
D. Chauhan,
...
T. Hideshima,
S. Treon,
Nikhil C. Munshi,
P. Richardson,
K. Anderson
|
8 |
2002 |
8
π
|
|
π¦
|
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
S. Treon,
Yanglin Cao,
Lian Xu,
Guang Yang,
Xia Liu,
Z. Hunter
|
8 |
2014 |
8
π¦
|
|
π’
|
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
11 auth.
Z. Hunter,
Lian Xu,
Guang Yang,
Yangsheng Zhou,
Xia Liu,
Yanglin Cao,
...
R. Manning,
C. Tripsas,
C. Patterson,
P. Sheehy,
S. Treon
|
8 |
2014 |
8
π’
|
|
π
|
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
8 auth.
C. Mitsiades,
S. Treon,
N. Mitsiades,
Yoshihito Shima,
P. Richardson,
R. Schlossman,
...
T. Hideshima,
K. Anderson
|
8 |
2001 |
8
π
|
